FDA
-
-
-
-
-
-
-
Roivant's mosliciguat shows PVR reduction in phase 2 PH-ILD trial
-
-
-
-
-
-
-
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on
-
-
-
-
-
-
-
Priovant enrolls first patients in Phase 3 cutaneous sarcoidosis trial
-
-
-
-
-
-
-
Priovant begins phase 2b/3 trial for brepocitinib in rare scalp disorder
-
-
-
-
-
-
-
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
-
335,223 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
